We analysed the results particularly in correlation to clinicopathological data, such as hormone receptor status, HER2 status and patient survival data, in order to validate ISG15 as a new prognostic marker and potential drug target in the treatment of human breast cancer. This evidence concerns the gene ISG15 and breast cancer.